Miastenia gravis: diagnóstico y tratamiento
*Correspondencia: Guillermo A. Suárez, MD. Department of Neurology. Mayo
Clinic. 200 1st ST S.W. Rochester, MN 55905. USA. E-mail: gsuarez@mayo.edu
Introduction. Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue
of different muscle groups. Myasthenia gravis may affect persons of all ages, but especially women aged 20 to 40 years. Development
and conclusions. The ocular, facial and bulbar muscles are most often involved in this disease. The muscle weakness of patients
with myasthenia gravis becomes worse with intercurrent episodes of infection, fever and physical or emotional exhaustion.
Respiratory infection (bacterial or viral) is the most frequent trigger factor. The presence of antibodies to acetylcholine receptors
in a patient with the clinical features of myasthenia gravis, confirms the diagnosis. Treatment is controversial. Each patient therefore
has to be treated individually, as no single treatment is suitable for all patients. Treatment may include anticholinesterase drugs,
corticosteroids, plasmapheresis, immunoglobulin, immunosuppressive drugs and thymectomy.